相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions
Agnieszka K. Witkiewicz et al.
BREAST CANCER RESEARCH (2014)
Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2
Giulio Rastelli et al.
CELL CYCLE (2014)
Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors
Diane A. J. van der Biessen et al.
CLINICAL CANCER RESEARCH (2014)
Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey
Gaele Mariaule et al.
MOLECULES (2014)
Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment
Michael Hallek
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Structural characterization of the cyclin-dependent protein kinase family
Jane A. Endicott et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2013)
Anticancer Therapeutic Strategies Based on CDK Inhibitors
Luca Esposito et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3)
Anders Poulsen et al.
JOURNAL OF MOLECULAR MODELING (2013)
Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors
Sunil Kumar Tripathi et al.
JOURNAL OF THEORETICAL BIOLOGY (2013)
An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors
Yan Li et al.
MOLECULAR BIOSYSTEMS (2013)
A Novel Approach to the Discovery of Small-Molecule Ligands of CDK2
Mathew P. Martin et al.
CHEMBIOCHEM (2012)
A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial
Tianhong Li et al.
INVESTIGATIONAL NEW DRUGS (2012)
P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines
Nitesh P. Shirsath et al.
MOLECULAR CANCER (2012)
BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
Gerhard Siemeister et al.
MOLECULAR CANCER THERAPEUTICS (2012)
FASCAPLYSIN as a Specific Inhibitor for CDK4: Insights from Molecular Modelling
Muhammad Imtiaz Shafiq et al.
PLOS ONE (2012)
Discovery of a Potential Allosteric Ligand Binding Site in CDK2
Stephane Betzi et al.
ACS CHEMICAL BIOLOGY (2011)
A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors
D. Mahadevan et al.
ANNALS OF ONCOLOGY (2011)
Cell cycle arrest in cultured neuroblastoma cells exposed to a bis(thiosemicarbazonato) metal complex
Laura Bica et al.
BIOMETALS (2011)
Cyclin-dependent kinases: bridging their structure and function through computations
Marco De Vivo et al.
FUTURE MEDICINAL CHEMISTRY (2011)
A novel PKC-ι inhibitor abrogates cell proliferation and induces apoptosis in neuroblastoma
Prajit Pillai et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2011)
The CDK inhibitors in cancer research and therapy
Jonas Cicenas et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Induction of Eosinophil Apoptosis by the Cyclin-Dependent Kinase Inhibitor AT7519 Promotes the Resolution of Eosinophil-Dominant Allergic Inflammation
Ana L. Alessandri et al.
PLOS ONE (2011)
Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis
Danzhi Huang et al.
BIOINFORMATICS (2010)
Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells
N. Johnson et al.
BRITISH JOURNAL OF CANCER (2010)
Pharmacologic profile of the oral novel pan-CDK inhibitor BAY 1000394 in chemosensitive and chemorefractory tumor models
Gerhard Siemeister et al.
CANCER RESEARCH (2010)
CDK Inhibitors: From the Bench to Clinical Trials
Flavio Rizzolio et al.
CURRENT DRUG TARGETS (2010)
Nuclear Targeting of Cyclin-Dependent Kinase 2 Reveals Essential Roles of Cyclin-Dependent Kinase 2 Localization and Cyclin E in Vitamin D-Mediated Growth Inhibition
Omar Flores et al.
ENDOCRINOLOGY (2010)
CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1
Bartlomiej Bartkowiak et al.
GENES & DEVELOPMENT (2010)
Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
Wei-Gang Tong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient Samples
Matthew S. Squires et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
David Parry et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound
Simona Caporali et al.
PHARMACOLOGICAL RESEARCH (2010)
SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples
Andrew Conroy et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity
Simak Ali et al.
CANCER RESEARCH (2009)
Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry
Peter de Bruijn et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2009)
Identifying Tumor Cell Growth Inhibitors by Combinatorial Chemistry and Zebrafish Assays
Jing Xiang et al.
PLOS ONE (2009)
A novel binding pocket of cyclin-dependent kinase 2
Hao Chen et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2009)
CDK inhibitors in cancer therapy: what is next?
Marcos Malumbres et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer
A. C. Rigas et al.
ONCOGENE (2007)
Cyclin B and cyclin A confer different substrate recognition properties on CDK2
Nick R. Brown et al.
CELL CYCLE (2007)
Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells
Stephane Larochelle et al.
MOLECULAR CELL (2007)
A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo
L. Bagella et al.
ONCOGENE (2007)
In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00
Kalpana S. Joshi et al.
MOLECULAR CANCER THERAPEUTICS (2007)
P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-reasistant cells and significant in vivo efficacy in tumor models
Kalpana S. Joshi et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Discovery of [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity
Xin-Jie Chu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
In vitro and in vivo activity of R547:: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials
Wanda DePinto et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells
Dongpo Cai et al.
CANCER RESEARCH (2006)
Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition
Heshu Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Cyclin-dependent kinase pathways as targets for cancer treatment
GI Shapiro
JOURNAL OF CLINICAL ONCOLOGY (2006)
Peptide inhibitors of protein kinases - discovery, characterisation and use
MA Bogoyevitch et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2005)
Mammalian cyclin-dependent kinases
M Malumbres et al.
TRENDS IN BIOCHEMICAL SCIENCES (2005)
Seliciclib (CYC202, R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1
DE MacCallum et al.
CANCER RESEARCH (2005)
Molecular motions of human cyclin-dependent kinase 2
CP Barrett et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation
C Gondeau et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
CAK-cyclin-dependent activating kinase - A key kinase in cell cycle control and a target for drugs?
G Lolli et al.
CELL CYCLE (2005)
The structure of cyclin E1/CDK2: implications for CDK2 activation and CDK2-independent roles
R Honda et al.
EMBO JOURNAL (2005)
Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors
C McInnes et al.
CHEMISTRY & BIOLOGY (2004)
Regulation of protein kinases: Controlling activity through activation segment conformation
B Nolen et al.
MOLECULAR CELL (2004)
A computational model of binding thermodynamics: The design of cyclin-dependent kinase 2 inhibitors
PA Sims et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)
SJ McClue et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Pharmacological inhibitors of cyclin-dependent kinases
M Knockaert et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2002)
Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: Synthesis, X-ray crystallographic analysis, and biological activities
KS Kim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2
LN Johnson et al.
PHARMACOLOGY & THERAPEUTICS (2002)
The role of Thr160 phosphorylation of Cdk2 in substrate recognition
JK Holmes et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2001)
Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A/indirubin-5-sulphonate
TG Davies et al.
STRUCTURE (2001)
Quinazolines as cyclin dependent kinase inhibitors
TM Sielecki et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Structure-activity relationship studies of flavopiridol analogues
KK Murthi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2000)
The Protein Data Bank
HM Berman et al.
NUCLEIC ACIDS RESEARCH (2000)
分享论文
